If you are wondering whether DexCom at around US$64 a share looks appealing or expensive, this article breaks down what that ...
DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...
DexCom’s fair value price target has been tweaked from US$85.85 to US$86.12 per share, a small shift that still matters if you are tracking what analysts are baking into their models. This move sits ...
DexCom has barely scratched the surface of its niche in the diabetes market. As a result of industry challenges, the stock's valuation has now come down. But from here, the stock looks well-positioned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results